Abstract
Oleh Hornykiewicz, one of the most accomplished neuropharmacologists of the 20th century passed away on May 26, 2020 at the age of 93. In 1939, Oleh’s father, a Ukrainian Catholic priest, fled with his young family from Soviet-occupied Ukraine and settled in Vienna. During his medical studies, Oleh became fascinated by pharmacology and in 1956 was awarded a fellowship to Oxford University (U.K.) where he worked with Dr. Hermann Blaschko, a pioneer in the study of enzymes of catecholamine synthesis and metabolism. At that time, it was still thought that dopamine was merely an intermediate in the synthesis of norepinephrine. Dr. Hornykiewicz demonstrated that even after its breakdown had been blocked, administration of dopamine or its precursor L-DOPA could elevate blood pressure in animal models. Dopamine was bioactive per se. Upon his return to Vienna in 1958, the young scientist began studying dopamine in the brain. Familiar with Parkinson’s Disease and intrigued by Arvid Carlsson’s finding that L-DOPA could counteract the akinesia of the reserpenized rat, Dr. Hornyckiewicz began to suspect that a dopamine deficiency mediated the motor symptoms of Parkinson’s disease. He developed new techniques, applied these to the study of postmortem brains, and demonstrated that Parkinson’s disease was associated with a dopamine deficiency in the basal ganglia. Shortly afterwards, he and Walter Birkmeyer observed how the intravenous administration of L-DOPA could awaken mute and akinetic patients with Parkinson’s disease. For the first time, a discreet chemical was both implicated in a complex brain disorder and could be used as a treatment. This stands as one of the seminal discoveries in neuropharmacology. To this day, L-DOPA remains a mainstay in the treatment of Parkinson’s disease. Over the following half-century Dr. Hornykiewicz continued his own work, generously mentored others and established brain banks in Vienna as well as in Toronto, Canada where he worked for many years. He received numerous awards, and was nominated for but not awarded the Nobel Prize in Medicine, in a decision that has remained controversial. He will remain forever, a brilliant star in the history of neuropharmacology.
Highlights
Двадцять шостого травня 2020 року у віці 93 років відійшов у вічність Олег Горникевич – один із найвидатніших фармакологів у ХХ століття в галузі нейронаук
that Parkinson's disease was associated with a dopamine deficiency in the basal ganglia
L-DOPA remains a mainstay in the treatment of Parkinson's disease
Summary
Двадцять шостого травня 2020 року у віці 93 років відійшов у вічність Олег Горникевич – один із найвидатніших фармакологів у ХХ століття в галузі нейронаук. Доктор Горникевич продемонстрував, що навіть після того, як його розпад заблоковано, введення дофаміну чи його вихідного продукту L-ДОФА може підвищити кров’яний тиск у тварин. Повернувшись до Відня в 1958 році, молодий науковець почав досліджувати дофамін у мозку. Що L-ДОФА може протидіяти акінезії щура, що отримав резерпін, доктор Горникевич почав підозрювати, що брак дофаміну запускав рухові симптоми хвороби
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have